TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with chronic noncancer pain severe enough to require continuous opioid therapy (a score of at least 5 in pain right now on a 11 point numeric rating scale) who have never received an opioid or are currently treated with a weak opioid, and who experience insufficient pain control.~Exclusion Criteria:~* Patients who have been treated with strong opioids (including hydromorphone and oxycodone) within the last 4 weeks prior to study inclusion or who will probably undergo any treatment (e.g. neurological techniques, surgery) within the next 6 months, which may abruptly alter degree or nature of pain experienced~* patients with a history of disease(s), current illness, or therapy which would preclude them from participation in the study~* and patients who are pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxycodone (Type: ACTIVE_COMPARATOR): None
- OROS hydromorphone HCl (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Completed 24 weeks of study drug treatment and study participation in either parent study, MVT-601-3101 or MVT-601-3102.~2. Is not expected to undergo gynecological surgery or other surgical procedures for treatment of endometriosis (including ablation, shaving, or excision) during the study, including during the Follow-Up Period, and the participant does not desire such treatment during this time frame.~3. Has agreed to continue to use only study-specified analgesic medications during the study and is not known to be intolerant to these.~Key Exclusion Criteria:~1. Has had a surgical procedure for treatment for endometriosis at any time during the parent study (MVT-601-3101 or MVT-601-3102).~2. Has any chronic pain or frequently recurring pain condition, other than endometriosis, that is treated with opioids or requires analgesics for ≥ 7 days per month.~3. Has a Z-score \< -2.0 or has a ≥ 7% decrease in bone mineral density from the parent study Baseline at lumbar spine, total hip, or femoral neck based on the parent study Week 24 DXA assessment of bone mineral density.~4. Has any contraindication to treatment with low-dose E2 and NETA, including:~   1. Known, suspected, or history of breast cancer;~  2. Known or suspected estrogen-dependent neoplasia;~  3. Active deep vein thrombosis or pulmonary embolism, or history of these conditions prior to the Week 24/Baseline visit;~  4. History of or active arterial thromboembolic disease, including stroke and myocardial infarction;~  5. Known anaphylactic reaction or angioedema or hypersensitivity to E2 or NETA;~  6. Known protein C, protein S, or antithrombin deficiency, or other known thrombophilia disorders, including Factor V Leiden;~  7. Migraine with aura;~  8. History of porphyria.~5. Had any of the following clinical laboratory abnormalities at the parent study Week 20 visit or, if available, any subsequent visit in one of the parent studies (MVT-601-3101 or MVT-601-3102):~   1. Alanine aminotransferase or aspartate aminotransferase \> 2.0 times the upper limit of normal (ULN); or~  2. Bilirubin (total bilirubin) \> 1.5 x ULN (or \> 2.0 x ULN if secondary to Gilbert syndrome or pattern consistent with Gilbert syndrome).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 51 Years
- Healthy Volunteers: f

Study Arms:
- Relugolix plus E2/NETA (Type: EXPERIMENTAL): Relugolix co-administered with E2/NETA for 80 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Promoting Tolerance to Peanut in High-Risk Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to consume solid food~* Allergy to eggs and/or severe eczema~* Informed consent obtained from parent or guardian.~Exclusion Criteria:~* Clinically significant chronic illness. Participants with eczema or recurrent wheeze are not excluded.~* Positive skin prick test for peanut allergen with a wheel diameter greater than 4 mm in the presence of a negative saline control~* Previous or current consumption of peanut protein that exceeds 0.2 g of peanut protein on at least one occasion or 0.5 g over a single week~* Investigator-suspected allergy to peanut protein~* Investigator-suspected allergy to peanut protein in care provider or current household member.~* Diagnosis of persistent asthma~* ALT (SGPT) or bilirubin greater than 2 times the upper limit of age-related normal value~* BUN or creatinine greater than 1.25 times the upper limit of age-related normal value~* Platelet count less than 100,000/mL, hemoglobin less than 9 g/dL, or investigator-suspected immunocompromise~* Unwillingness or inability to comply with study requirements and procedures

- Gender: ALL
- Minimum Age: 4 Months
- Maximum Age: 10 Months
- Healthy Volunteers: f

Study Arms:
- Peanut Consumption Group (Type: EXPERIMENTAL): Participants on this arm will consume peanut protein.
- Peanut Avoidance Group (Type: NO_INTERVENTION): Participants on this arm will avoid peanut as per United Kingdom (UK) public health recommendations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Everyday Memory Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 70 - 85 years of age~* in fair to good health~* free of major neurocognitive impairment~* English speaking~* endorsed Smartphone and computer users (or willing to learn)~Exclusion Criteria:~* diagnosis of any major neurological problems (e.g. stroke, Parkinson's disease, dementia)~* 1.5 SD below age-normed mean (or lower) on the TICS~* low computer and smart phone literacy~* and poor self-rated health.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Everyday Metacognitive Memory (Type: EXPERIMENTAL): Training in techniques for managing memory demands in everyday life
- Memory Strategy Control (Type: ACTIVE_COMPARATOR): Trains the use of memory strategies for learning new associations and concepts

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Identifying and Treating Depression in Hemodialysis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* currently on hemodialysis at a CDC dialysis unit~* English speaking~* able to provide informed consent~Exclusion Criteria:~* on hemodialysis for less than 3 months~* comorbid psychotic, bipolar, substance use dependence, Alzheimer's or dementia~Not eligible for Phase II (intervention) if currently on antidepressant medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluoxetine Group (Type: EXPERIMENTAL): Approximately 96 patients will be enrolled into the intervention (Phase II) over the duration of the entire study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Preterm Infants' Paracetamol Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* preterm infants born \< 32 weeks gestational age~Exclusion Criteria:~* congenital malformation~* lethal disease~* chromosomal abnormality~* persistent pulmonary hypertension of a newborn

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- Paracetamol effect on ductus (Type: EXPERIMENTAL): The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.
- Paracetamol effect on pain (Type: EXPERIMENTAL): The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of chronic myeloid leukemia associated with BCR-ABL quantifiable by RQ-PCR Documented CCyR by bone marrow or BCR-ABL\<1% IS in the past 12 months Persistent disease demonstrated by two PCR positive tests 3 months apart both during the past 6 months.~Treatment with imatinib for at least 2 years with 400 mg or 600 mg and a stable dose No other current or planned anti-leukemia therapies~Exclusion Criteria:~Patient has evidence of rising PCR (a confirmed \>1 log increase in previous 6 months) Patient has received another investigational agent within last 6 months or tyrosine kinase inhibitors (TKIs) other than imatinib Prior allogeneic stem cell transplantation~Impaired cardiac function including any one of the following:~Inability to monitor the QT interval on electrocardiogram (ECG) Long QT syndrome or a known family history of long QT syndrome. Clinically significant resting brachycardia (\<50 beats per minute) QTc \> 450 msec on baseline ECG (using the QTcF formula). If QTcF \>450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc Myocardial infarction within 12 months prior to starting study Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension) History of or presence of clinically significant ventricular or atrial tachyarrhythmias Administration of cytokine therapy (e.g. G-CSF, GM-CSF or SCF) within 4 weeks prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.
- Imatinib (Type: ACTIVE_COMPARATOR): Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated inform consent~* Out-patient, clinical diagnosis of COPD~* Men or women at the age of 40 or over~Exclusion Criteria:~* A history of asthma~* Seasonal allergic rhinitis before 40 years of age~* Patients with significant or unstable ischemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the investigator or other disorder

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Bricasol®
- 2 (Type: EXPERIMENTAL): Bricasol® + Pulmicort®
- 3 (Type: EXPERIMENTAL): Bricasol® + Symbicort®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Colonic Propionate, Appetite, and Weight Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* overweight or obese ((BMI) of 25-35 kg/m2)~* healthy~* aged between 18 and 65 years~Exclusion Criteria:~* Weight change of ≥ 3kg in the preceding 2 months~* Undergone any weight loss surgery or gastric procedures to promote weight loss~* Current smokers~* Substance abuse~* Excess alcohol intake~* Pregnancy~* Diabetes~* Cardiovascular disease~* Cancer~* Gastrointestinal disease e.g. inflammatory bowel disease or irritable bowel syndrome~* Kidney disease~* Liver disease~* Pancreatitis~* Use of medications likely to interfere with energy metabolism, appetite regulation and hormonal balance, including: anti-inflammatory drugs or steroids, antibiotics, androgens, phenytoin, erythromycin or thyroid hormones.~Any participants with the above conditions would already have an altered pattern of hormones and inflammatory molecules because of their disease process and would therefore give us confounding or misleading results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- experimental group (Type: EXPERIMENTAL): 10 g of Inulin-Propionate Esters will be administered per day
- Inulin (Type: ACTIVE_COMPARATOR): 10 g of Inulin will be administered per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ECG with atrial fibrillation at the emergency department~* Heart rate \> 70bpm~* Symptoms most probable due to atrial fibrillation~* Duration of symptoms \< 36 hours~* \> 18 years of age~* Able and willing to sign informed consent~* Able and willing to use MyDiagnostick~Exclusion Criteria:~* Signs of myocardial infarction on ECG~* Hemodynamic instability (systolic blood pressure \< 100mm Hg, heart rate \> 170 bpm)~* Presence of pre-excitation syndrome~* History of Sick Sinus Syndrome~* History of unexplained syncope~* History of persistent AF (episode of AF lasting more than 48 hours)~* Acute heart failure~* Currently enrolled in another clinical trial~* Deemed unsuitable for participation by attending physician

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Care (Type: ACTIVE_COMPARATOR): Pharmacological cardioversion and/or electrical cardioversion
- Wait-and-see Approach (Type: EXPERIMENTAL): Rate control drugs only (metoprolol, verapamil or digoxin)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- All patients who undergo care for lung cancer or an undiagnosed lung mass within the Baptist Memorial Health Care Corporation's hospitals from January 1, 2009 until the end of the defined study period will be eligible for inclusion in the data collection for this study. In addition, caregivers of patients within the same institution and within the study window, clinical care providers (doctors and nurses) who have taken care of patients within the eligible institutions during the study window.~Exclusion Criteria:~* Patients who do not have a radiology-identified lung lesion or lung cancer are excluded from this study.~* Patients not receiving care within the Baptist Memorial Healthcare Corporation are excluded from this study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Multidisciplinary Clinic Patients (Type: None): : 150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients
- Serial Care Patients (Type: None): 150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients = 450 patients Since Baptist Health Care System manages \>800 new cases each year, 300 of which are expected to be seen in multidisciplinary clinic, in practice, we conservatively expect to be able to recruit 150 cases from multidisciplinary clinic and 300 matched serial care controls (1:2 match) in 18 months.
- Multidisciplinary Caregivers (Type: None): Consenting caregivers of consented multidisciplinary clinic patients (patients seen by multiple specialists at a single appointment time).
- Serial Care Caregivers (Type: None): Consenting caregivers of consented serial care patients (patients who receive the current system of linear, sequential, referral-based care delivery).
- Clinical Providers (Type: None): Clinical providers who referred at least 5 patients to the multidisciplinary program and consented to the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Woman currently using MIRENA for contraception or menorrhagia with duration use between 4 years 3 months and 4 years 9 months and willingness to continue with the method.~* Normal size uterus at insertion, corresponding to sound measure of 6-10 cm.~* Clinically normal cervical smear result within 12 preceding months or at screening.~* Clinically normal breast examination findings. For patients \>/= 40 years at screening, a clinically normal mammography result within 12 preceding months or at screening is required.~Exclusion Criteria:~* Menopausal symptoms impairing patient's quality of life or current estrogen therapy for menopausal symptoms.~* Known or suspected pregnancy.~* Any distortion of the uterine cavity, including congenital or acquired uterine anomalies and fibroids distorting the uterine cavity.~* Current or recurrent pelvic inflammatory disease.~* Abnormal uterine bleeding of unknown origin.~* Acute cervicitis or vaginitis not responding to treatment.~* History of, diagnosed or suspected genital or other malignancy (excluding treated squamous cell carcinoma of the skin), and untreated cervical dysplasia.~* Any active acute liver disease or liver tumor.

- Gender: FEMALE
- Minimum Age: 23 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: PLACEBO_COMPARATOR): None
- Arm 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Peri-operative rATG-perfusion of Solid Transplants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients receiving a kidney or liver transplant from deceased donors~Exclusion Criteria:~* Hepatitis C Virus/Human Immunodeficiency Virus, undergoing re-transplantation or under a public guardian

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AP-KTx/LTx (Type: ACTIVE_COMPARATOR): Transplant recipients receiving an rATG-perfused kidney or liver
- CP-KTx/LTx (Type: PLACEBO_COMPARATOR): Transplant recipients receiving a control-perfused kidney or liver.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete